WO2024259250A3 - 5-ht2a receptor modulators and methods of use thereof - Google Patents

5-ht2a receptor modulators and methods of use thereof Download PDF

Info

Publication number
WO2024259250A3
WO2024259250A3 PCT/US2024/034032 US2024034032W WO2024259250A3 WO 2024259250 A3 WO2024259250 A3 WO 2024259250A3 US 2024034032 W US2024034032 W US 2024034032W WO 2024259250 A3 WO2024259250 A3 WO 2024259250A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
compounds
receptor modulators
ht2a receptor
ht2a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2024/034032
Other languages
French (fr)
Other versions
WO2024259250A2 (en
Inventor
Paul Galatsis
Urjita H. SHAH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Transneural Therapeutics Inc
Original Assignee
Transneural Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transneural Therapeutics Inc filed Critical Transneural Therapeutics Inc
Priority to CN202480053782.7A priority Critical patent/CN121843926A/en
Publication of WO2024259250A2 publication Critical patent/WO2024259250A2/en
Publication of WO2024259250A3 publication Critical patent/WO2024259250A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The disclosure provides compounds, e.g., compounds of Formula I, and their use in treating medical diseases or disorders, such as psychiatric and neurological disorders. Pharmaceutical compositions and methods of making various benzisoxazole and benzoisothiazole compounds are provided. The compounds are contemplated to be modulators of the 5-hydroxytryptamine 2A (5-HT2A) receptor.
PCT/US2024/034032 2023-06-16 2024-06-14 5-ht2a receptor modulators and methods of use thereof Ceased WO2024259250A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202480053782.7A CN121843926A (en) 2023-06-16 2024-06-14 5-HT2A receptor modulators and their usage

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363508569P 2023-06-16 2023-06-16
US63/508,569 2023-06-16

Publications (2)

Publication Number Publication Date
WO2024259250A2 WO2024259250A2 (en) 2024-12-19
WO2024259250A3 true WO2024259250A3 (en) 2025-04-10

Family

ID=93852768

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2024/034032 Ceased WO2024259250A2 (en) 2023-06-16 2024-06-14 5-ht2a receptor modulators and methods of use thereof

Country Status (2)

Country Link
CN (1) CN121843926A (en)
WO (1) WO2024259250A2 (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352811A (en) * 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
US5140029A (en) * 1989-01-09 1992-08-18 Janssen Pharmaceutica N.V. 2-aminopyrimidinone derivatives
US20060252768A1 (en) * 2003-03-26 2006-11-09 Kazutoshi Watanabe 2,3,6-Trisubstituted-4-pyrimidone derivatives
US20200262916A1 (en) * 2019-02-15 2020-08-20 Stc. Unm Mammalian Atg8 Proteins Control Autolysosomal Biogenesis Through SNARES
WO2023141225A1 (en) * 2022-01-19 2023-07-27 Onsero Therapeutics Inc. Fused heterocycles as 5-ht2a receptor agonists

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4352811A (en) * 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
US5140029A (en) * 1989-01-09 1992-08-18 Janssen Pharmaceutica N.V. 2-aminopyrimidinone derivatives
US20060252768A1 (en) * 2003-03-26 2006-11-09 Kazutoshi Watanabe 2,3,6-Trisubstituted-4-pyrimidone derivatives
US20200262916A1 (en) * 2019-02-15 2020-08-20 Stc. Unm Mammalian Atg8 Proteins Control Autolysosomal Biogenesis Through SNARES
WO2023141225A1 (en) * 2022-01-19 2023-07-27 Onsero Therapeutics Inc. Fused heterocycles as 5-ht2a receptor agonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE Pubchem 12 February 2015 (2015-02-12), "SCHEMBL795369", XP093303835, Database accession no. SID 227075288 *
SHASTRI, RA: "Review on Synthesis of 3-Substituted 1,2-Benzisoxazole Derivatives", CHEMICAL SCIENCE TRANSACTIONS, vol. 5, no. 1, 2016, pages 8 - 20, XP055581116, DOI: 10.7598/cst2016.1120 *
SIVALA MUNICHANDRA REDDY, CHINTHA VENKATARAMAIAH, POTLA KRISHNA MURTHY, CHINNAM SAMPATH, CHAMARTHI NAGA RAJU: "In silico docking studies and synthesis of new phosphoramidate derivatives of 6-fluoro-3-(piperidin-4-yl)benzo[d]isoxazole as potential antimicrobial agents", JOURNAL OF RECEPTOR AND SIGNAL TRANSDUCTION RESEARCH., MARCEL DEKKER, NEW YORK, NY., US, vol. 40, no. 5, 1 September 2020 (2020-09-01), US , pages 486 - 492, XP009562410, ISSN: 1079-9893, DOI: 10.1080/10799893.2020.1752719 *

Also Published As

Publication number Publication date
WO2024259250A2 (en) 2024-12-19
CN121843926A (en) 2026-04-10

Similar Documents

Publication Publication Date Title
WO2005080343A3 (en) 3-substituted 1,5-diphenylpyrazole derivatives useful as cb1 modulators
BRPI0407253A (en) Heterocyclyl-3-sulfonylindazoles as ligands 5-hydroxytryptamine-6 process for their preparation, their uses in the preparation of a pharmaceutical composition and a pharmaceutical composition comprising said compounds
AU2002359164A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
TW200502221A (en) Novel lactams and uses thereof
TW200504034A (en) Therapeutic agents
WO2004087677A3 (en) Pyrimidin-4-one derivatives and their use as p38 kinase modulators
CA2534570A1 (en) Substituted 2,3-dihydro-1h-isoindol-1-one derivatives and methods of use
CA2417897A1 (en) Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
UA83862C2 (en) Thiazole derivatives as cannabinoid receptor modulators
WO2007100366A3 (en) Quinolone m1 receptor positive allosteric modulators
EA200701296A1 (en) 3,5-Disposable and 3,5,7-triple-substituted 3H-oxazolo-and 3H-thiazolo [4,5-D] pyrimidin-2-she and their medicines
TW200635903A (en) Therapeutic agents
WO2003048164A3 (en) Adenosine a2a receptor antagonists
WO2005037798A3 (en) Amide or thiomide derivatives and their use in the treatment of pain
NO20072089L (en) Benzimidazole derivatives, compositions containing them, their preparation and their use
WO2019217890A8 (en) Novel functionalized lactams as modulators of the 5-hydroxytryptamine receptor 7 and their method of use
MX2023010711A (en) Phenalkylamines and methods of making and using the same.
EA200601194A1 (en) NEW DERIVATIVES OF BENZOFURANE USED FOR THE PREVENTION OR TREATMENT OF DISTURBANCES ASSOCIATED WITH 5-HT-RECEPTOR
TW200509933A (en) Therapeutic agents
AU2002359162A1 (en) Use of oxindole derivatives in the treatment of dementia related diseases, alzheimer's disease and conditions associated with glycogen synthase kinase-3
TW200633986A (en) Therapeutic agents
IL176546A0 (en) Imidazoline derivatives having cb1-antagonistic activity
WO2003070728A3 (en) Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
NO20064951L (en) 1,3,4-oxadiazole-2-ones as PPAR delta modulators and their use
TW200604196A (en) New quinuclidine derivatives and pharmaceutical compositions comprising them

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE